Evidence map›Paper›PMID 41044171›Full record

Observational studyScientific reports2025

Reliable on-treatment prognostication and target identification with a customized assay for circulating tumor DNA in patients with newly diagnosed pancreatic cancer.

Alexandra Petersson, Maja Svensson, Sofie Olsson Hau, Rebecka Bergström, Johan Lindberg, Markus Mayrhofer, Subhayan Chattopadhyay, Jakob Eberhard, Markus Heidenblad, Karin Leandersson and 2 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alexandra PeterssonDivision of Oncology and Therapeutic Pathology, Department of Clinical Sciences Lund, Lund University, Lund, 221 85, Sweden.
Maja SvenssonDivision of Oncology and Therapeutic Pathology, Department of Clinical Sciences Lund, Lund University, Lund, 221 85, Sweden.
Sofie Olsson HauDivision of Oncology and Therapeutic Pathology, Department of Clinical Sciences Lund, Lund University, Lund, 221 85, Sweden.
Rebecka BergströmDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Johan LindbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Markus MayrhoferDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Subhayan ChattopadhyayDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Jakob EberhardDivision of Oncology and Therapeutic Pathology, Department of Clinical Sciences Lund, Lund University, Lund, 221 85, Sweden.
Markus HeidenbladCenter for Translational Genomics, Lund University, Lund, Sweden.
Karin LeanderssonCancer Immunology, Department of Translational Medicine, Lund University, Malmö, Sweden.
David GisselssonNational Bioinformatics Infrastructure Sweden and Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
Karin JirströmDivision of Oncology and Therapeutic Pathology, Department of Clinical Sciences Lund, Lund University, Lund, 221 85, Sweden. karin.jirstrom@med.lu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The vast majority of patients with pancreatic cancer present with unresectable disease and precision medicine is lagging behind. Circulating tumor DNA (ctDNA) has emerged as a promising tool, both as a proxy for tumor burden and for capturing tumor heterogeneity, but optimal gene panels and prognostic cutoffs remain to be determined. Herein, we applied ultra-deep ctDNA sequencing using a customized panel targeting 23 genes and six frequently altered chromosomes on plasma samples obtained before, during and after chemotherapy from 60 patients enrolled in a prospective clinical study. At baseline, positive versus negative ctDNA was not prognostic, neither in the adjuvant nor in the palliative setting, but in palliative patients, an independent prognostic cutoff could be calculated from the absolute number of mutated DNA molecules. Median overall survival was 3.7 months in the ctDNA

Indexed as

Biomarkers, TumorCirculating Tumor DNAPancreatic NeoplasmsAdultAgedAged, 80 and overFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationPrognosisProspective StudiesBiomarkers, TumorCirculating Tumor DNAChemotherapyCtDNAOn-treatment monitoringPancreatic cancerPrognosis

Identifiers

PMID41044171
PMCPMC12494785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.